KR20160002681A - 골격 성장 지연 질환의 예방 또는 치료에 사용하기 위한 용해성 섬유아세포 성장 인자 수용체 3(fgr3) 폴리펩티드 - Google Patents

골격 성장 지연 질환의 예방 또는 치료에 사용하기 위한 용해성 섬유아세포 성장 인자 수용체 3(fgr3) 폴리펩티드 Download PDF

Info

Publication number
KR20160002681A
KR20160002681A KR1020157022203A KR20157022203A KR20160002681A KR 20160002681 A KR20160002681 A KR 20160002681A KR 1020157022203 A KR1020157022203 A KR 1020157022203A KR 20157022203 A KR20157022203 A KR 20157022203A KR 20160002681 A KR20160002681 A KR 20160002681A
Authority
KR
South Korea
Prior art keywords
fgfr3
polypeptide
skeletal
sfgfr3
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020157022203A
Other languages
English (en)
Korean (ko)
Inventor
엘비르 구즈
Original Assignee
인썸(인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰메디칼르)
위니베르씨떼 뽈 싸바띠에 뚤루즈 3
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인썸(인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰메디칼르), 위니베르씨떼 뽈 싸바띠에 뚤루즈 3 filed Critical 인썸(인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰메디칼르)
Publication of KR20160002681A publication Critical patent/KR20160002681A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020157022203A 2013-01-16 2013-01-16 골격 성장 지연 질환의 예방 또는 치료에 사용하기 위한 용해성 섬유아세포 성장 인자 수용체 3(fgr3) 폴리펩티드 Withdrawn KR20160002681A (ko)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2013/001480 WO2014111744A1 (en) 2013-01-16 2013-01-16 A soluble fibroblast growth factor receptor 3 (fgr3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders

Publications (1)

Publication Number Publication Date
KR20160002681A true KR20160002681A (ko) 2016-01-08

Family

ID=48289519

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020157022203A Withdrawn KR20160002681A (ko) 2013-01-16 2013-01-16 골격 성장 지연 질환의 예방 또는 치료에 사용하기 위한 용해성 섬유아세포 성장 인자 수용체 3(fgr3) 폴리펩티드
KR1020217013228A Withdrawn KR20210054026A (ko) 2013-01-16 2014-01-16 골격 성장 지연 질환의 예방 또는 치료에 사용하기 위한 용해성 섬유아세포 성장 인자 수용체 3(fgr3) 폴리펩티드
KR1020157022078A Expired - Fee Related KR102249454B1 (ko) 2013-01-16 2014-01-16 골격 성장 지연 질환의 예방 또는 치료에 사용하기 위한 용해성 섬유아세포 성장 인자 수용체 3(fgr3) 폴리펩티드

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020217013228A Withdrawn KR20210054026A (ko) 2013-01-16 2014-01-16 골격 성장 지연 질환의 예방 또는 치료에 사용하기 위한 용해성 섬유아세포 성장 인자 수용체 3(fgr3) 폴리펩티드
KR1020157022078A Expired - Fee Related KR102249454B1 (ko) 2013-01-16 2014-01-16 골격 성장 지연 질환의 예방 또는 치료에 사용하기 위한 용해성 섬유아세포 성장 인자 수용체 3(fgr3) 폴리펩티드

Country Status (19)

Country Link
US (5) US20150344855A1 (enExample)
EP (2) EP2945967B1 (enExample)
JP (3) JP2016506914A (enExample)
KR (3) KR20160002681A (enExample)
CN (1) CN105121464B (enExample)
AU (2) AU2013373679A1 (enExample)
CA (2) CA2898415A1 (enExample)
DK (1) DK2945967T3 (enExample)
EA (2) EA201591324A1 (enExample)
ES (1) ES2796743T3 (enExample)
HU (1) HUE049556T2 (enExample)
IL (2) IL239810A0 (enExample)
MX (2) MX372787B (enExample)
PE (1) PE20151664A1 (enExample)
PL (1) PL2945967T3 (enExample)
PT (1) PT2945967T (enExample)
SG (2) SG11201505488XA (enExample)
SI (1) SI2945967T1 (enExample)
WO (2) WO2014111744A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017188696A1 (ko) * 2016-04-25 2017-11-02 장부다 Vr 공간에서 사용자 인터페이스를 제공하는 방법, 디바이스 및 기록매체

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150344855A1 (en) 2013-01-16 2015-12-03 INSERM (Institut National de la Santé et de la Recherche Médicale A Soluble Fibroblast Growth Factor Receptor 3 (FGR3) Polypeptide For Use In The Prevention Or Treatment Of Skeletal Growth Retardation Disorders
CA2972865A1 (en) * 2015-01-07 2016-07-14 Therachon Sas Soluble fgfr3 decoys for treating skeletal growth disorders
KR102432192B1 (ko) * 2016-07-07 2022-08-12 화이자 인코포레이티드 가용성 섬유아세포 성장 인자 수용체 3(sfgfr3) 폴리펩티드 및 이의 용도
EP3684394A1 (en) * 2017-09-20 2020-07-29 Pfizer Inc. Treatment of abnormal visceral fat deposition using soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides
CN108410803B (zh) * 2018-03-28 2019-02-05 湖南源品细胞生物科技有限公司 一种诱导脂肪干细胞成软骨分化的培养方法和培养液
CN110272900B (zh) * 2019-04-19 2024-03-26 中国人民解放军陆军军医大学 用于制备骨骼发育异常猪模型的sgRNA及其应用
WO2022106976A1 (en) 2020-11-18 2022-05-27 Pfizer Inc. Stable pharmaceutical formulations of soluble fgfr3 decoys
JP2022184798A (ja) 2021-06-01 2022-12-13 ファイザー・インク ｓＦＧＦＲ３ポリペプチドを生産するための細胞培養方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308236D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Dna vectors
WO1996041523A1 (en) * 1995-06-12 1996-12-27 Yeda Research And Development Co., Ltd. Fgf9 as a specific ligand for fgfr3
US7067144B2 (en) 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
US7598055B2 (en) 2000-06-28 2009-10-06 Glycofi, Inc. N-acetylglucosaminyltransferase III expression in lower eukaryotes
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US7863020B2 (en) 2000-06-28 2011-01-04 Glycofi, Inc. Production of sialylated N-glycans in lower eukaryotes
US7029872B2 (en) 2000-06-28 2006-04-18 Glycofi, Inc Methods for producing modified glycoproteins
US7625756B2 (en) 2000-06-28 2009-12-01 GycoFi, Inc. Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
US20040109850A1 (en) * 2000-12-18 2004-06-10 Neelam Jaiswal Treatment of bone disorders by modulation of fgfr3
IL142118A0 (en) 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
IL159177A0 (en) 2001-06-20 2004-06-01 Prochon Biotech Ltd Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
BRPI0203172B8 (pt) * 2001-09-28 2021-05-25 Nakao Kazuwa composição farmacêutica para acondroplasia
JP4252746B2 (ja) * 2001-10-05 2009-04-08 一和 中尾 軟骨無形成症治療剤
JP2003104908A (ja) * 2001-09-28 2003-04-09 Ichikazu Nakao 軟骨無形成症治療剤
US7332299B2 (en) 2003-02-20 2008-02-19 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes
IL156495A0 (en) * 2003-06-17 2004-01-04 Prochon Biotech Ltd Use of fgfr3 antagonists for treating t cell mediated diseases
AU2005216547B2 (en) * 2004-02-24 2009-03-12 Allergan, Inc. Botulinum toxin screening assays
NZ565511A (en) 2005-07-22 2011-03-31 Five Prime Therapeutics Inc Compositions and methods of treating disease with FGFR fusion proteins
US8101721B2 (en) 2006-06-15 2012-01-24 Fibron Ltd. Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
US8962556B2 (en) 2006-09-28 2015-02-24 Prochon Biotech Ltd. FGF-2 variants having N-terminal deletions and increased receptor selectivity and uses thereof
PE20081250A1 (es) 2006-11-28 2008-10-07 Centelion FUSIONES Fc CON RECEPTOR PARA FGF SOLUBLE MODIFICADAS, CON ACTIVIDAD BIOLOGICA MEJORADA
WO2008133873A2 (en) * 2007-04-25 2008-11-06 Aveo Pharmaceuticals, Inc. Fgf-binding fusion proteins
US8426396B2 (en) 2008-01-08 2013-04-23 Shriners Hospitals For Children Treatment for achondroplasia
WO2010002862A2 (en) 2008-07-01 2010-01-07 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (fgfr3) binding proteins
CN102171343B (zh) 2008-08-04 2017-07-14 戊瑞治疗有限公司 Fgfr细胞外结构域酸性区突变蛋白
AR073770A1 (es) 2008-10-20 2010-12-01 Imclone Llc Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden
ES2549769T3 (es) 2009-03-25 2015-11-02 Genentech, Inc. Anticuerpos anti-FGFR3 y métodos que emplean los mismos
CN101585866B (zh) * 2009-07-02 2011-10-05 中国人民解放军第三军医大学野战外科研究所 调节fgfr3活性的多肽及其筛选方法和应用
WO2011034940A1 (en) 2009-09-15 2011-03-24 Five Prime Therapeutics, Inc. Hair growth methods using fgfr4 extracellular domains
PT2498799T (pt) 2009-11-13 2016-11-04 Five Prime Therapeutics Inc Utilização de proteínas do domínio extracelular rfcf1 para tratar cancros caracterizados por mutações ativadoras dependentes de ligando em rfcf2
WO2011084711A2 (en) 2009-12-17 2011-07-14 Five Prime Therapeutics, Inc. Hair growth methods using fgfr3 extracellular domains
WO2011088196A2 (en) 2010-01-14 2011-07-21 Yale University Inhibitors of receptor tyrosine kinases (rtk) and methods of use thereof
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
JP6055779B2 (ja) * 2010-12-27 2016-12-27 アレクシオン ファーマシューティカルズ， インコーポレイテッド ナトリウム利尿ペプチドを含む組成物およびその使用方法
CN102219860B (zh) 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 FGFR-Fc融合蛋白及其用途
CA2853358A1 (en) 2011-10-24 2013-05-02 Halozyme, Inc. Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
FR2984325A1 (fr) 2011-12-14 2013-06-21 Sanofi Sa Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique
CA2880013C (en) 2012-07-24 2022-11-29 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
BR112015001724A2 (pt) 2012-07-27 2018-04-03 Genentech Inc métodos de tratamento de condições relacionadas a fgfr3
EP4223770A3 (en) 2012-11-05 2023-10-18 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
US20150344855A1 (en) 2013-01-16 2015-12-03 INSERM (Institut National de la Santé et de la Recherche Médicale A Soluble Fibroblast Growth Factor Receptor 3 (FGR3) Polypeptide For Use In The Prevention Or Treatment Of Skeletal Growth Retardation Disorders
RS60593B1 (sr) 2014-01-24 2020-08-31 Ngm Biopharmaceuticals Inc Antitela koja vezuju domen 2 beta-kloto i postupci za njihovu upotrebu
CA2972865A1 (en) 2015-01-07 2016-07-14 Therachon Sas Soluble fgfr3 decoys for treating skeletal growth disorders
KR102432192B1 (ko) 2016-07-07 2022-08-12 화이자 인코포레이티드 가용성 섬유아세포 성장 인자 수용체 3(sfgfr3) 폴리펩티드 및 이의 용도
EP3684394A1 (en) 2017-09-20 2020-07-29 Pfizer Inc. Treatment of abnormal visceral fat deposition using soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017188696A1 (ko) * 2016-04-25 2017-11-02 장부다 Vr 공간에서 사용자 인터페이스를 제공하는 방법, 디바이스 및 기록매체

Also Published As

Publication number Publication date
PL2945967T3 (pl) 2020-11-16
SG11201505140XA (en) 2015-07-30
PT2945967T (pt) 2020-05-28
EA201591055A1 (ru) 2016-04-29
AU2013373679A1 (en) 2015-08-13
US20150353624A1 (en) 2015-12-10
JP2016506912A (ja) 2016-03-07
MX2015009142A (es) 2015-11-06
EP2945967A1 (en) 2015-11-25
CA2896978A1 (en) 2014-07-24
MX372787B (es) 2020-07-03
MX2019013857A (es) 2020-01-20
HK1217959A1 (zh) 2017-01-27
US20210032608A1 (en) 2021-02-04
AU2014206844A1 (en) 2015-07-16
HUE049556T2 (hu) 2020-09-28
EA201591324A1 (ru) 2016-01-29
JP6995069B2 (ja) 2022-02-04
IL239996A0 (en) 2015-08-31
JP2019107006A (ja) 2019-07-04
US20150344855A1 (en) 2015-12-03
PE20151664A1 (es) 2015-11-28
KR20150122136A (ko) 2015-10-30
SI2945967T1 (sl) 2020-10-30
ES2796743T3 (es) 2020-11-30
US11814654B2 (en) 2023-11-14
CN105121464B (zh) 2021-05-07
KR20210054026A (ko) 2021-05-12
US10724014B2 (en) 2020-07-28
US20210032607A1 (en) 2021-02-04
EP3736285A1 (en) 2020-11-11
WO2014111744A1 (en) 2014-07-24
CA2898415A1 (en) 2014-07-24
WO2014111467A1 (en) 2014-07-24
SG11201505488XA (en) 2015-08-28
EP2945967B1 (en) 2020-04-15
JP2016506914A (ja) 2016-03-07
KR102249454B1 (ko) 2021-05-07
US11702642B2 (en) 2023-07-18
DK2945967T3 (da) 2020-07-13
US20200199545A1 (en) 2020-06-25
CN105121464A (zh) 2015-12-02
IL239810A0 (en) 2015-08-31

Similar Documents

Publication Publication Date Title
US11702642B2 (en) Soluble fibroblast growth factor receptor 3 (FGR3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
EP3967755B1 (en) Soluble npp1 for use in a method for treating pseudoxanthoma elasticum
RS53302B (sr) Alkalna fosfataza koja je usmerena na kosti, pribor i postupci upotrebe
US20180087119A1 (en) Crystallized oxalate decarboxylase and methods of use
JP2020015733A (ja) 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド
EP2507266B1 (en) TREATMENT OF IgE-MEDIATED DISEASE
HK40039498A (en) A soluble fibroblast growth factor receptor 3 (fgr3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
HK1217959B (en) A soluble fibroblast growth factor receptor 3 (fgr3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
HK40116513A (en) Methods of treating tissue calcification
HK40070846A (en) Soluble npp1 for use in a method for treating pseudoxanthoma elasticum
BR112017005986B1 (pt) Complexo que compreende um primeiro heterodímero e um segundo heterodímero, composição farmacêutica e uso do complexo

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203

WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid
R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000